Tesamorelin (brand name Egrifta) is FDA-approved for reduction of visceral adiposity in HIV patients, produces similar effects to sermorelin including increased deep sleep, is more long-lasting than sermorelin, and is typically taken 3 times per week rather than 5 times per week.
factualpending
Speaker
Andrew HubermanEvidence Quote
“tesamorelin...Egrifta...FDA approved drug for the reduction of visceral adiposity...more long-lasting than sermorelin...three times per week, not five times per week”
Created: 8/11/2026, 6:26:50 AM
Your notes
Loading notes...